At the FDA Panel on May 12, BMTI is seeking the approval of their Augment bone graft. In the report, J.P. Morgan said, "BioMimetic appears well-prepared for the meeting with a solid clinical data package. The co has been conducting mock training sessions to prepare for its May 12th date, and communications with the agency thus far have yielded no surprises. BMTI and FDA have been in consistent contact heading into the panel, and the co feels comfortable with the nature of requests."
Source: http://www.benzinga.com/analyst-ratings/analyst-color/11/05/1052275/j-p-morgan-expects-positive-fda-panel-for-bmti-and-is-ra#ixzz1MF3tZXIu
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM